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Introduction: Redundant collagen deposition at sites of healing dermal wounds results in hypertrophic scars.
Adipose-derived stem cells (ADSCs) exhibit promise in a variety of anti-fibrosis applications by attenuating collagen
deposition. The objective of this study was to explore the influence of an intralesional injection of ADSCs on
hypertrophic scar formation by using an established rabbit ear model.
Methods: Twelve New Zealand albino rabbits were equally divided into three groups, and six identical punch
defects were made on each ear. On postoperative day 14 when all wounds were completely re-epithelialized, the
first group received an intralesional injection of ADSCs on their right ears and Dulbecco’s modified Eagle’s medium
(DMEM) on their left ears as an internal control. Rabbits in the second group were injected with conditioned
medium of the ADSCs (ADSCs-CM) on their right ears and DMEM on their left ears as an internal control. Right ears
of the third group remained untreated, and left ears received DMEM. We quantified scar hypertrophy by measuring
the scar elevation index (SEI) on postoperative days 14, 21, 28, and 35 with ultrasonography. Wounds were
harvested 35 days later for histomorphometric and gene expression analysis.
Results: Intralesional injections of ADSCs or ADSCs-CM both led to scars with a far more normal appearance and
significantly decreased SEI (44.04 % and 32.48 %, respectively, both P <0.01) in the rabbit ears compared with their
internal controls. Furthermore, we confirmed that collagen was organized more regularly and that there was a
decreased expression of alpha-smooth muscle actin (α-SMA) and collagen type Ι in the ADSC- and ADSCs-CM-injected
scars according to histomorphometric and real-time quantitative polymerase chain reaction analysis. There was no
difference between DMEM-injected and untreated scars.
Conclusions: An intralesional injection of ADSCs reduces the formation of rabbit ear hypertrophic scars by decreasing
the α-SMA and collagen type Ι gene expression and ameliorating collagen deposition and this may result in an
effective and innovative anti-scarring therapy.Introduction
After injury in dermal tissue, hypertrophic scars can
occur because of abnormal extracellular matrix depos-
ition and remodeling, especially with collagen [1].
This scar tissue is usually raised and inflexible with
itching, pain, and redness as a result of an overabun-
dant wound matrix and might give rise to significant* Correspondence: wgcao@sina.com
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Today there are all kinds of therapies for hypertrophic
scars, including excision, intralesional corticosteroid
injection, compression, laser, and interferon injection.
However, none of these treatments has been confirmed
to be effective in fully avoiding excessive scar tissue
formation and regenerating healthy dermal tissue [3,
4]. Hence, it remains a challenge for clinicians to cure
hypertrophic scarring.
Major mechanisms during the wound-healing process
have already been well studied [5]. Hypertrophic scars
occur because of specific factors during the wound-tributed under the terms of the Creative Commons Attribution License (http://
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and remodeling. The immune function disorders of T cells
and macrophages, accompanied by an extensive inflamma-
tory response, can form void-filling, non-functional tissue
and result in the evolvement of scars [6–8]. Reactive oxygen
species (ROS) are also a potent driver of deposition of
collagen, which is a kind of highly cytotoxic compound se-
creted by neutrophils for wound sterilization [9, 10]. Trans-
forming growth factor-beta 1 (TGF-β1), a known booster
of dermal fibrosis, is a critical collagen-stimulating element
in fibroblasts. Besides, TGF-β1 inhibits matrix metallopro-
teinase (MMP) expression resulting in the accumulation of
collagen fibers within the wound sites [11–13]. Myofibro-
blast differentiation is another intensifier of fibrosis during
wound healing. Myofibroblasts, differentiated from fibro-
blasts in an injury environment, are intended for narrowing
the margin of the wounds and accelerating the re-
epithelialization by contraction. However, at the same time,
they produce tensed, excessive, and irregularly arranged
collagen bundles and bring on over-contraction that char-
acterizes hypertrophic scars [14, 15]. Prolonged wound
healing usually results in hypertrophic scarring. Conse-
quently, it is very important to ensure the formation of an
adequate microvascular network and development into a
permanent vascular network during the healing process;
otherwise, wound closure will be impaired and hyper-
trophic scars will occur [16].
During the wound-healing process, any abnormality can
have a negative influence on tissue regeneration and con-
tribute to the hypertrophic scar formation. From a
therapeutic perspective, medicines that modulate the ab-
normalities in the period of wound healing may be of
benefit in the therapy of scars. According to scientific ef-
forts on many fibrotic diseases, adipose-derived stem
cell (ADSC) therapy may be a hopeful method of pre-
venting fibrosis through decreasing inflammation, inhi-
biting TGF-β1, and favoring tissue regeneration at the
wound site [17–19]. Our investigations through the
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Fig. 1 Experiment design. Three groups of rabbits were enrolled. ADSCs, A
first, second, and third groups, respectively. The left ears of all groups recei
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Methods
Rabbit ear hypertrophic scar model
The rabbit ear hypertrophic scar model as described previ-
ously [20] has been well established. Briefly, 12 adult New
Zealand albino rabbits (each weighing 2.5 to 3 kg) were
given anesthesia under sterile conditions in preparation for
wounding based on a protocol approved by the Animal
Care and Experiment Committee of the Shanghai Jiao Tong
University School of Medicine. Six circular, full-thickness,
1-cm wounds were made to the bare cartilage on the
ventral surface of each ear by using a trephine, and the
epidermis, dermis, and perichondrium were carefully
removed. The wounds were covered with erythromycin
eye ointment and cleaned of secretions the next day.
The study has excluded samples of infective or necrotic
wounds (Fig. 1).
Preparation of ADSCs and conditioned medium
Four-week-old New Zealand albino rabbits were sacri-
ficed, and groin fat pads were collected, minced, and
digested with 0.075 % collagenase type I (Sigma-Aldrich,
St. Louis, MO, USA) at 37 °C for 45 min with constant
shaking. The cell suspension was centrifuged at 1200×g
for 10 min. Then the pellet was resuspended and main-
tained at 37 °C in a humidified atmosphere containing
95 % air and 5 % CO2 in regular medium—low-glucose
Dulbecco’s modified Eagle’s medium (DMEM), 10 %
fetal bovine serum (FBS), 1 % penicillin/streptomycin;
Invitrogen, Carlsbad, CA, USA—which was changed
every 3 days until 80–90 % confluency was reached. The
cells were cultured to the third passage and used for the
following steps.
Six-well plates were used for seeding ADSCs (about
5×104 cells/cm2) in the third passage. Sixteen hours after
seeding, the regular medium was replaced by DMEM
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min, and filtered through a 0.22-μm syringe filter.
Identification of ADSCs
Cells were verified by flow cytometry and examined for
multiple lineage differentiation as requested by the Inter-
national Society for Cellular Therapy. For flow cytometric
analysis, ADSCs of the third passage were incubated with
monoclonal PE-conjugated antibodies for CD34, CD105,
HLA-DR, and CD73 or with FITC-conjugated antibodies
for CD14, CD90, and CD45 at room temperature for 30
min (BD Pharmingen, San Diego, CA, USA). Isotype con-
trol IgG was used to stain the cells as control. The cells
were subsequently washed with phosphate-buffered saline
(PBS), fixed with 4 % formaldehyde, and analyzed on a
FACScan flow cytometer (Becton-Dickinson, San Jose,
CA, USA).
For adipogenesis assessment, the cells were incubated
in adipogenic medium which included the regular cul-
ture medium supplemented with 0.5 mM 1-methyl-3-
isobutylxanthine, 1 mM dexamethasone, 10 μl/l insulin,
and 100 mM indomethacin (Sigma-Aldrich). The
medium was refreshed every 3 days. Adipogenesis was
confirmed 21 days later by neutral lipid droplets in the
cytoplasm and positive oil red O staining observed in an
inverted-phase contrast microscope.
For osteogenic differentiation, we incubated cells at
100 % confluency with an osteoinducing medium con-
taining the regular culture medium further supple-
mented with 10−8 M dexamethasone, 0.3 g/l L
−glutamine, 10 mM β-phospherglycerol, and 50 mg/l
ascorbic acid (all from Sigma-Aldrich). Calcium de-
posits, the main characteristic of osteogenesis, were
confirmed by positive staining with alizarin red S
(Sigma-Aldrich).
Intralesional injection
ADSCs were harvested at the third passage and labeled
with Dil (Invitrogen) in accordance with the instructions of
the manufacturer. In brief, ADSCs were washed twice with
PBS after being harvested, suspended in Dil dilution (5 μl/
ml in DMEM), and incubated at 37 °C for 20 min. After in-
cubation, they were washed twice again and suspended in
low-glucose DMEM for injection. Four million ADSCs in
0.2 ml of DMEM were slowly and carefully injected into
the center of each lesion from the edge of the wound with
a 29-G needle. Similarly, 0.2 ml of ADSCs-CM or DMEM
was injected into each lesion in the same way.
Evaluation of scars
Photos were taken every week to observe any external
changes to the wounds since the operation. Ultrasonog-
raphy of the lesion was detected by an ultrasound ma-
chine (MyLabOne, Esaote, Italy) before and 2, 3, 4, and5 weeks after the surgery to record any internal changes
of the scar.
Histological analysis
Scars were harvested for histologic detection 35 days after
the operation. They were bisected and immediately fixed in
10 % formalin. Afterwards, the scars were embedded in
paraffin and cut into sections. For scar elevation index (SEI)
qualification, sections were stained with hematoxylin and
eosin, examined under microscope (Nikon Eclipse E400;
Nikon, Tokyo, Japan), and qualified with a digital image
analysis system (NIS-Elements Basic Research; Nikon
Instech Co., Kanagawa, Japan). The measurement was done
twice by a blinded examiner, and averaged values were
used. Further evaluation of collagen fiber arrangement was
done with Masson trichrome staining.
Tracing of ADSCs
After being harvested, scar tissues were bisected and
fixed in 4 % paraformaldehyde containing 10 % sucrose
at 4 °C for 12 h and then 30 % sucrose for 24 h. The
specimens were then embedded in OCT compound and
stored at −80 °C until use. They were cut at 10 μm,
mounted onto SuperFrost-Plus charged slides (Citotest,
Jiangsu, China), and washed three times with PBS.
After being air-dried for 10 min, they were subjected
to 4′,6−diamidino−2−phenylindole (DAPI) (1 μg/ml;
Sigma-Aldrich) for nuclear staining and photographed
with fluorescence microscopy.
Total RNA extraction and real-time quantitative
polymerase chain reaction
Scar tissues were snap-frozen in liquid nitrogen imme-
diately after harvest. Before total RNA could be ob-
tained, the scar samples were homogenized with an
electronic high-speed homogenizer (Scientz, Zhejiang,
China). Total RNA was separated with TRIzol reagent
(Invitrogen, Life Technologies, Carlsbad, CA, USA) in
accordance with the instructions of the manufacturer.
The concentration and purity of the total RNA were
determined with optical density 260/280 nm measure-
ments (Nanodrop, Isogen, Scotland, UK), and cDNA
was generated from the total RNA by reverse tran-
scription with oligonucleotide (dT) primers. The
cDNA was diluted in DNase-free water (1:25) and then
amplified with a SYBR Green real-time PCR Kit
(TaKaRa, Shiga, Japan) with primer pairs for rabbit
alpha-smooth muscle actin (α-SMA), collagen type I,
and β-actin. The primer pairs were the following:
ACTA2 (National Center for Biotechnology Informa-
tion (NCBI) Gene ID: 100009271) forward 5′-CAGGG
AGTAATGGTTGGAAT-3′ and reverse 5′-TCTCAAA
CATAATCTGGGTCA-3′, COL1A2 (NCBI Gene ID:
100008997) forward 5′-CCCAACCAAGGATGCACTA-
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and ACTB (NCBI Gene ID: 100009272) forward 5′-
GCTATTTGGCGCTGGACTT-3′ and reverse 5′-
GCGGCTCGTAGCTCTTCTC-3′. We used an iCycler
Real-Time PCR detection system to perform the gene
expression analysis (Applied Biosystems, Foster City,
CA, USA). Results were standardized with reference
gene β-actin, and the 2−DDCt and fold changes were
calculated manually.
Statistical analysis
Wounds were made, treated, and harvested in a matched
fashion with their internal controls. GraphPad Prism 6
(GraphPad Software, Inc., La Jolla, CA, USA) was used to
analyze the data. The Student’s t test was used to make theFig. 2 Characterization and differentiation of rabbit ADSCs. a Flow cytometry a
CD14, and HLA-DR and positive for CD73, CD90, and CD105 and this is consiste
isotype control; red line: sample). b Cultured human ADSCs display a typical fibro
and osteogenic lineages in vitro, as demonstrated by positive oil red O staining
formation (d). Original magnifications: ×40 (a, b, d) and ×100 (c). ADSC adipose-comparison of the SEI and gene expression in treated scars
and their internal controls. Statistical significance was con-
sidered when P < 0.05.
Results
Identification of ADSCs
ADSCs exhibited fibroblast morphology and expanded
easily when cultured in regular medium in vitro. They
were confirmed positive for CD73, CD90, and CD105
and negative for CD34, CD45, CD14, and HLA-DR ex-
pression according to flow cytometry analysis of stem
cell-related surface markers (Fig. 2a). They can also be
successfully trans-differentiated into adipocytes and
osteocytes, and this was confirmed by using oil red O
staining and alizarin red S (Fig. 2b).nalysis shows that the majority of ADSCs are negative for CD45, CD34,
nt with the typical mesenchymal stem cell surface marker profile (black line:
blast-like morphology (a) and are able to differentiate between adipogenic
(b), lipid droplet formation (c), and alizarin red S staining for calcium deposit
derived stem cell
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hypertrophy
Gross examination
On postoperative day 14, all wounds were totally re-
epithelialized on gross examination. After re-epithelization,
a stiff and visibly raised scar gradually formed in both the
control and untreated scars. By contrast, a significant im-
provement of scars, which were less visible and softer, was
noticed in both ADSC- and ADSCs-CM-treated scars
(Fig. 3).
Ultrasonography and calculated SEI
We employed ultrasonography to monitor the changes
of wounds. It recorded the accurate thickness of the
scar tissue from the epithelium to cartilage and calcu-
lated the SEI; this was quite different from traditional
methods that measured the total thickness, including
the cartilage and tissue below. Ultrasonography of theFig. 3 Gross examination images. Both ADSC- and ADSCs-CM-treated scars
visible compared with their internal controls (DMEM 1 and DMEM 2), which
adipose-derived stem cell, ADSCs-CM conditioned medium of the adipose-wounds showed a gradually growing SEI that was fi-
nally distinct from and exceeded the surrounding un-
wounded skin in the control and untreated scars,
whereas a slight change was shown in the ADSC- or
ADSCs-CM-treated ones (Figs. 4 and 7a).
Hematoxylin-and-eosin staining and calculated SEI
On postoperative day 35, hematoxylin-and-eosin stain-
ing showed that the control and untreated scars were
obviously thickened with slight contraction. However,
the ADSC- or ADSCs-CM treated ones were flatter and
thinner and this is consistent with the gross macro-
scopic findings (Fig. 5). The SEIs in treated scars of groups
1 and 2 were much lower than their internal controls
(group 1: 1.08 ± 0.05 versus 1.93 ± 0.09, P < 0.01, n = 24;
group 2: 1.33 ± 0.10 versus 1.97 ± 0.11, P < 0.01, n = 24).
However, there is no significant difference between un-
treated and DMEM-injected scars in group 3 (group 3:improved significantly on gross examination and were softer and less
gradually became raised, red, and stiff after re-epithelization. ADSC
derived stem cells, DMEM Dulbecco’s modified Eagle’s medium
Fig. 4 Ultrasonography of the wounds. Ultrasonography shows a gradually growing thickness of the scars in the internal control sides (DMEM 1
and DMEM 2) but almost no change in the ADSC- and ADSCs-CM-treated scars. ADSC adipose-derived stem cell, ADSCs-CM conditioned medium
of the adipose-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium
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Fig. 7b).
Masson trichrome staining
Masson trichrome staining was used for observation of
collagen deposition. On postoperative day 35, collagen
fibers were dense and irregularly arranged in the DMEM
and untreated scars. Conversely the deposition was
eased and collagen fibers were well arranged in the
ADSC and ADSCs-CM injection scars (Fig. 6).
Detection of gene expression
The effect of ADSCs and ADSCs-CM on α-SMA and colla-
gen type Ι mRNA expression was measured by quantitativeFig. 5 Histologic analysis of wounds. On postoperative day 35, scars treated wi
nothing and DMEM (DMEM 1, 2, and 3) were obviously thickened with contrac
magnifications: ×40. ADSC adipose-derived stem cell, ADSCs-CM conditioned me
Eagle’s mediumpolymerase chain reaction by using the housekeeping gene
β-actin as an internal standard control. Both treatments
inhibited α-SMA (Fig. 7c) and collagen type Ι (Fig. 7d)
mRNA expression in groups 1 and 2 (P < 0.01). There was
no difference between DMEM injection and untreated
scars in terms of α-SMA and collagen type Ι mRNA
expression.
Vehicles (DMEM) have no effect on scar reduction
Group 3 (right ear: untreated; left ear: DMEM injection)
was set up for the detection of the therapeutic effect of
DMEM injection. The results show that DMEM injec-
tion has no effect on scar reduction. In group 3, the SEI
values (Fig. 7b) in the DMEM injection scars wereth ADSCs or ADSCs-CM were even (a, b), whereas the scars treated with
tion (c, d, e, f). Cells were stained with hematoxylin and eosin. Original
dium of the adipose-derived stem cells, DMEM Dulbecco’s modified
Fig. 6 Masson trichrome staining. Masson trichrome staining was used for the evaluation of collagen fiber organization. Collagen fibers
were dense and disorderly in the internal control and untreated scars (b, d). In the ADSC- or ADSCs-CM-treated scars, collagen fibers were
regularly arranged (a, c). Original magnifications: ×200 (a, b) and ×400 (c, d). ADSC adipose-derived stem cell, ADSCs-CM conditioned
medium of the adipose-derived stem cells
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ment. Also, there is no significant difference of α-SMA
and collagen type I gene expression (Fig. 7c, d) between
untreated and DMEM-injected scars in group 3. Thus, it
also confirmed that DMEM injection did not contribute
to the improvement of scars in groups 1 and 2.
ADSCs were more effective than ADSCs-CM in reducing
hypertrophic scars
Both ADSCs and ADSCs-CM can reduce the scar hyper-
trophy compared with their internal controls. We also
found that ADSCs were more effective than ADSCs-CM in
further quantitative analysis of the SEI values and mRNA
levels. The SEI values were significantly lower in ADSC in-
jection scars of group 1 compared with ADSCs-CM-treated
ones of group 2 (ΔP < 0.01) (Fig. 7b). Also, there was a de-
crease of mRNA levels of α-SMA and collagen type Ι in
ADSC therapy in contrast to ADSCs-CM treatment (both
*P < 0.05) (Fig. 7c, d).
Viable ADSCs were confirmed in the cell injection group
Before the injection, ADSCs were marked with Dil, a
flourochrome used for tracing live cells. They were de-
tected by frozen sections with a fluorescent microscope
after harvesting. We recorded a large number of green
fluorochrome-labeled cells with blue-fluorescence nuclei
evenly distributed in the ADSC-injected scar tissues 3weeks after the initial treatment (Fig. 8). Thus, a large
number of live cells were confirmed in the ADSC-
treated scars, which probably contributed to the inhib-
ition of hypertrophic scars.
Discussion
Devastating consequences such as organ dysfunction
or body disfigurements can result from excess scar
formation, which is secondary to surgical or traumatic
injuries. However, it has been interestingly observed
in several clinical studies that scar tissue from some
patients with burn injuries transformed into those his-
tologically similar to normal tissues after undergoing
fat transplantation [21–23]. Although this mechanism
has not been fully understood, it was conjectured that
the performance of stem cells from adipose tissue
might give rise to such histologic and clinical scar
improvement.
Potential causes for hypertrophic scars revealed by our
knowledge of the wound-healing process might contrib-
ute to the advance of an effective cure for hypertrophic
scar formation [1, 2, 24]. Wound healing is a complex
process that consists of three sequential yet superim-
posed phases: inflammatory, cellular proliferation, and
remodeling phases. Hypertrophic scars can occur as a
result of an abnormality in the process. Many studies
demonstrate that mesenchymal stem cells (MSCs) have












































































































































Fig. 7 SEI detected by ultrasonography and hematoxylin-and-eosin staining and gene expression analysis. a The SEI detected by ultrasonography
increased significantly in the internal control scars (DMEM 1 and DMEM 2) in comparison with scars treated with ADSCs and ADSCs-CM on
postoperative day 14, 21, 28, and 35. b Hematoxylin-and-eosin staining showed that the SEI decreased significantly in scars treated with ADSCs or
ADSCs-CM in comparison with their internal controls on postoperative day 35 (44.04 % and 32.48 %, respectively, **P < 0.01 versus internal control). The SEI
of ADSC injection scars was much lower than that of ADSCs-CM-treated scars (Δ P < 0.01). There was no significant difference between untreated and
DMEM injection scars (P > 0.05). c, d The effect of ADSCs and ADSCs-CM on α-SMA and collagen type Ι mRNA expression was measured by quantitative
polymerase chain reaction by using the housekeeping gene β-actin as an internal standard control. Both treatments inhibited α-SMA (c) and collagen type
Ι (d) mRNA expression in groups 1 and 2 (both **P < 0.01 versus internal control). ADSC treatment resulted in an even lower gene expression of α-SMA
and collagen type Ι in comparison with ADSCs-CM injection (*P < 0.05). There was no difference between DMEM injection and untreated scars in terms of
α-SMA and collagen type Ι mRNA expression (P > 0.05). α-SMA alpha-smooth muscle actin, ADSC adipose-derived stem cell, ADSCs-CM conditioned
medium of the adipose-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium, SEI scar elevation index
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ing during the process.
Discovered by Zuk et al. in 2001 [25], ADSCs are a
kind of MSCs but are more abundant and can be readily
acquired, separated, and cultured. They are now widely
used as seed cells in tissue engineering as well as in
studies promoting wound healing, whitening, anti-aging,
and anti-fibrosis [26–30]. Plenty of research on the effect
of ADSCs in fibrosis was previously done in animal
models or cells. A treatment of injecting ADSCs on in-
jured vocal folds has been performed by one group,
which demonstrated the ability of ADSCs to prevent
vocal fold atrophy and scarring in a canine animal model
because of their multipotential ability in the regeneration
of injured vocal folds [17]. Another group studied the in-
fluence of ADSC therapy on cardiac remodeling and con-
tractility by using the acute myocardial infarction mouse
model and observed great improvement in ventricular re-
modeling and cardiac function with smaller infarct size andless scar formation. They found that ADSCs can migrate
into infarct sites and integrate into scar areas and that some
expressed the endothelial marker which might have favored
increased vascular density in the injured site [19]. Further-
more, one group found that ADSC treatment can prevent
elastosis and fibrotic changes of the tunica albuginea by
testing the influence of locally injected ADSCs with a
Peyronie’s disease rat model in the active phase [18].
However, the effect of ADSCs on scar formation of the
skin has not been studied. Our study investigated the
anti-fibrosis effect of ADSCs on the hypertrophic scar
formation in vivo. We injected ADSCs and their condi-
tioned medium in the wound on postoperative day 14
after the completion of re-epithelization on a rabbit ear
hypertrophic scar model. Both treatments resulted in
much lower SEI, more regular collagen arrangement,
and decreased expression of α-SMA and collagen type Ι,
suggesting that ADSC or ADSCs-CM injections can re-
spectively suppress the formation of hypertrophic scars.
Fig. 8 Tracing of viable ADSCs. Viable ADSCs were confirmed in the cell injection group. A large number of Dil-labeled ADSCs were observed (green
fluorescence) in the ADSC-injected scar tissue 3 weeks after the initial treatment (a, b). DAPI was used for nuclear staining. Original magnifications: ×40
(a) and ×100 (b). ADSC adipose-derived stem cell, DAPI 4′,6-diamidino-2-phenylindole
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cytokines secreted by ADSCs, such as IL-10, adrenome-
dullin, and hepatocyte growth factor (HGF) [31–33].
They have been proven to suppress fibrosis by various
mechanisms, including reducing the expression of TGF-
β1 and collagen and promoting the expression of MMPs,
thus accelerating the turnover of the extracellular matrix
[34–37]. The cytokine HGF has also proven the ability
of inhibiting myofibroblast differentiation which contrib-
utes to the limitation of pro-fibrotic functions of myo-
fibroblasts [15]. During the wound-healing period of
proliferation, angiogenesis plays an important role in
supplying the fibroblasts with enough nutrients for theformation of an occasional granulation matrix [16].
Also secreted by ADSCs, vascular endothelial growth
factor A and basic fibroblast growth factor can offer
strong mitogenic cues to accelerate migration, prolifer-
ation, and differentiation of microvascular endothelial
cells and promote vascular stability [38–41].
Besides, we observed an even lower SEI and gene ex-
pression of α-SMA and collagen type Ι in ADSC injec-
tion scars than in ADSCs-CM-treated ones. Thus, it can
be speculated that ADSCs inhibit hypertrophic scar for-
mation through more than secreted anti-fibrotic factors.
Once they have entered the injury site, the MSCs are acti-
vated by the inflammatory environment in the wound to
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glandin E2 expression and upregulating cyclooxygenase-2
activity [42], which favors wound healing over inflammation
and reduces the pro-fibrotic effect that can coincidently
exist with immune function disorders of T cells and
macrophages in extended inflammation [7, 8]. During
the period of wound healing, long exposure to ROS is an
intensifier of fibrosis by a mechanism that includes induc-
tion of TGF-β1 [9, 43]. Also, MSCs can upregulate indu-
cible nitric oxide when they interact with T cells in a pro-
inflammatory environment which can change the ROS/
RNS (reactive nitrogen species) balance to stop fibrotic
tissues from forming [10].
An additional mechanism by which MSCs may accel-
erate the cutaneous wound-healing process has been
suggested by many studies [44–46]. MSCs could directly
take part in the structural regeneration of epidermal and
dermal tissues by trans-differentiating into keratinocytes
when interacting with native epidermal cells. Recently,
one group used a rabbit ear hypertrophic scar model to
illustrate that MSCs can attenuate scar formation in a
p53-dependent manner [47].
We observed a large number of ADSCs labeled with
green fluorochrome in the scar tissue 3 weeks after the ini-
tial treatment, confirming the active involvement of ADSCs
in wound regeneration. However, we have not come up
with an effective method to detect the survival rate of
ADSCs, because of the difficulty in counting the number of
cells in the scar tissue, and we also failed to trace the final
outcome of the ADSCs because of the temporary effect of
Dil labeling. Further research with techniques for cell
counting in tissues and prolonged cell labeling will be
needed to study the survival rate of transplanted ADSCs
and whether transplanted ADSCs trans-differentiate into
local cells, such as vascular endothelial cells and fibroblasts.
Conclusions
This study tested the anti-scaring effect of ADSCs and
their conditioned medium, in excess of 140 wounds,
adopting our well-founded rabbit ear hypertrophic scar
model. We have demonstrated that ADSCs can suppress
the formation of hypertrophic scars through more than
secreting anti-fibrosis cytokines when injected locally
in vivo. This is a preliminary study that to our know-
ledge has not been established by others. Although we
need to further investigate ADSCs, it would be novel to
adopt them as anti-scarring agents, and there is im-
mense potential for clinical ramifications in the field of
hypertrophic scar prevention and treatment.
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